Home

Minimieren ausblenden Im Wesentlichen bloomberg teva Scheinen bevorzugen Schwindel

Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg

Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The  Times of Israel
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel

Allergan becomes largest shareholder in Teva - Globes
Allergan becomes largest shareholder in Teva - Globes

Teva Is On The Prowl And Its Investors Are Taking Notice | Mint
Teva Is On The Prowl And Its Investors Are Taking Notice | Mint

Teva (TEVA), AbbVie (ABBV) to Pay $161.5 Million in West Virginia Opioid  Case - Bloomberg
Teva (TEVA), AbbVie (ABBV) to Pay $161.5 Million in West Virginia Opioid Case - Bloomberg

Teva Pharmaceutical Industries is in talks to manufacture and distribute  COVID vaccines | Fortune
Teva Pharmaceutical Industries is in talks to manufacture and distribute COVID vaccines | Fortune

Teva Gets Generic Price-Fixing Securities Suits Consolidated
Teva Gets Generic Price-Fixing Securities Suits Consolidated

Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict - Bloomberg
Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict - Bloomberg

Teva Abandons Search to Make Covid-19 Vaccine for Partners - Bloomberg
Teva Abandons Search to Make Covid-19 Vaccine for Partners - Bloomberg

Drug giants line up for Irish legal battle over patents - Independent.ie
Drug giants line up for Irish legal battle over patents - Independent.ie

Teva, Allergan ready to pay $5B to settle thousands of opioid lawsuits (TEVA)  | Seeking Alpha
Teva, Allergan ready to pay $5B to settle thousands of opioid lawsuits (TEVA) | Seeking Alpha

Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg

Teva CEO Says Drugmaker Will Fight Price-Fixing Charges - Hamodia.com
Teva CEO Says Drugmaker Will Fight Price-Fixing Charges - Hamodia.com

Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC - TheStreet
Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC - TheStreet

Teva Generic Price-Fixing Securities Suit Gets Class Status (1)
Teva Generic Price-Fixing Securities Suit Gets Class Status (1)

Teva: Reportedly Planning Thousands of Layoffs in the U.S. | Fortune
Teva: Reportedly Planning Thousands of Layoffs in the U.S. | Fortune

How Uggs, Hoka, and Tevas Helped Build Deckers' $2.5 Billion Ugly-Shoe  Empire - Bloomberg
How Uggs, Hoka, and Tevas Helped Build Deckers' $2.5 Billion Ugly-Shoe Empire - Bloomberg

Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg

Israel's Teva offering free drugs to settle U.S. opiods case - Business -  Haaretz.com
Israel's Teva offering free drugs to settle U.S. opiods case - Business - Haaretz.com

Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says -  Bloomberg
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg

Inside the Mad Dash to Bring You Cheap, Generic Viagra
Inside the Mad Dash to Bring You Cheap, Generic Viagra

Glaxo's Win in Case Against Teva Lifts Other Drugmakers - Bloomberg
Glaxo's Win in Case Against Teva Lifts Other Drugmakers - Bloomberg

Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement  Settlement | Ctech
Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement | Ctech

US states accuse Teva and other drugmakers of colluding to inflate prices  over 1,000%
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%

Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg

Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech

Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube